Slide Show: Lung Cancer Highlights From ASCO 2014

June 20, 2014

This slide show highlights some of the top studies and news on lung cancer to come out of the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago.

References:

1. Roth JA, Sullivan SD, Ravelo A, et al. Low-dose computed tomography lung cancer screening in the Medicare program: Projected clinical, resource, and budget impact. Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting; Abstract 6501. Read More.

2. Perol M, Ciuleanu TE, Arrieta O, et al. REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy. Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting; Abstract LBA8006. Read More.

3. Janne PA, Ramalingam SS, Yang JCH, et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC). Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting; Abstract 8009. Read More.

4. Thatcher N, Hirsch FR, Szczesna A, et al. A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting; Abstract 8008. Read More.

5. Kato T, Seto T, Nishio M, et al. Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial. Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting; Abstract 8005. Read More.